More than one hundred different mutations in the gene encoding rhodopsin are associated with a group of retinal degenerations including retinitis pigmentosa, congenital stationary night blindness and retinitis punctata albescens. Given this large heterogeneity of mutations, it would be ideal to develop mutation-independent therapies for these diseases. We describe use of RNA interference (RNAi) and specifically short hairpin RNAs (shRNAs) expressed from DNA templates to silence both normal and mutant (P23H) human rhodopsin alleles by 94.3472.17 and 94.971.9%, respectively, in human embryonic retinoblasts. Degeneracy of the genetic code was used to engineer a codonexchanged mRNA (cmRNA) that demonstrated complete resistance to silencing by the shRNA. Simulation of autosomal dominant retinitis pigmentosa in cell culture through triple transfection of DNAs expressing a cmRNA, a P23H mRNA and an shRNA revealed shRNA-mediated silencing, specifically of P23H rhodopsin by 90.6475.19% and no loss of rhodopsin translation from the cmRNA in those cells. In addition, we present data on two alternative shRNA sequences targeting human rhodopsin. Our results have implications for the treatment of a very large variety of retinal degenerations in a mutation-independent manner.
The first step in vision involves the absorption of light by opsins present in the outer segments of rod and cone photoreceptors. 1 Mutations in human rod opsin (rhodopsin) are the most common cause of autosomal dominant retinitis pigmentosa (www.sph.uth.tmc.edu/ RetNet). Other retinal diseases associated with mutations in rhodopsin include congenital stationary night blindness (CSNB) and retinitis punctata albescens (RPA). 2, 3 More than one hundred different mutations have previously been identified in the gene encoding rhodopsin (complete list of mutations available at www.retinainternational.com). Hence, one important hurdle to therapy for RP, CSNB or RPA patients is the need for tailor-made, specific therapies targeted to each mutation, especially in the cases involving autosomal dominant inheritance. Although possible, sequence-specific therapies are impractical from several standpoints, including the probable need to evaluate the efficacy of each therapy separately in animal models and optimization prior to its use in patients -a significantly time consuming and economic hurdle. An alternative approach would be to develop therapies that are mutation independent. One potential solution to this problem is to silence all rhodopsin alleles (mutant and normal) and to complement them with an allele that is not subject to silencing. To the best of our knowledge, use of such a strategy was first proposed by Montgomery and Dietz 4 for the potential treatment of Marfan syndrome by antisense targeting of fibrillin-1 and more recently applied using ribozymes in vitro. 5 Recent developments in our understanding of mRNA silencing (reviewed in Baulcombe 6 ) through the use of the endogenous RNA interference (RNAi) machinery present in eukaryotic cells allows for a related and potentially more efficient approach. In this schema, endogenous mutant and wild-type rhodopsin mRNA in the photoreceptors might be silenced by an ectopic short hairpin RNA (shRNA) that targets both the mutant and wild-type mRNA, and that degraded mRNA trans complemented by an ectopic transgene engineered to produce an mRNA resistant to that same shRNA. Production of a rhodopsin protein identical in sequence to wild-type rhodopsin may be achieved through the degeneracy of the genetic code, that is, engineering a cDNA to produce a codon exchanged mRNA (cmRNA). In this report, we augment our earlier studies 7 by providing proof of principle that use of RNAi in such a schema is extremely efficient and may translate to the development of therapies for a large variety of retinal degenerations. In general, use of RNAi in this schema has the potential to be utilized for the treatment of a variety of other genetic diseases.
Two promoters that have previously been used to successfully drive expression of an shRNA for the purposes of silencing endogenous mRNA or mRNA associated with an ectopic transgene include the H1 RNA promoter and a modified CMV promoter. 8, 9 In order to compare and select the promoter most efficient for our studies, we cloned an shRNA sequence previously shown 9 to silence green fluorescent protein (GFP) efficiently in front of an H1 RNA promoter -pSuperGFPi ( Figure 1a) . The ability of pSuperGFPi in silencing GFP was compared to pmCMVmpAGFPi (kindly provided by Beverly Davidson, University of Iowa) -a plasmid that contains the exact same shRNA sequence, except that expression is regulated by a modified CMV promoter. 9 In contrast to the short termination signal of pSuperGFPi, pmCMVmpAGFPi has a longer polyadenylation signal resulting in a 63 nt transcript. Either plasmid was cotransfected with a plasmid expressing a destabilized GFP-pd2EGFP-N1 (Clontech) into the human embryonic retinoblast cell line 911. 10 As a control, pd2EGFP-N1 was cotransfected with a plasmid expressing the same shRNA from either the H1 RNA or CMV promoter that is not specific to GFP -pSuperRhoi1 or pmCMVmpARhoi1, respectively (detailed below). At 40 h post-transfection, the number of GFP-positive cells was counted by FACS. We found that shRNA expressed from the H1 RNA promoter was capable of reducing the observed number of GFP-positive cells by 62.973.55%. In the case of the shRNA expressed from a CMV promoter under the same conditions, we observed a reduction in the number of GFP-positive cells of 33.174.17% (Figure 1b ). In addition, we observed a decrease in the mean fluorescence intensity of 76.472.0% by GFP-positive cells when pSuperGFPi was used to silence GFP. A decrease in the mean fluorescence intensity was not observed for pmCMVmpAGFPi.
To address whether silencing of GFP was occurring at the level of RNA, we examined RNA prepared from the above experiment by qualitative Northern blot analysis. As expected, we found a reduction in the total amount of GFP mRNA when the cells were coexpressing an shRNA targeting GFP relative to the coexpression of a non-GFPtargeting shRNA (data not shown). Based on these collective data, we selected the H1 RNA promoter for our rhodopsin studies.
We compared the ability of three different shRNA molecules expressed from the H1 RNA promoter to silence wild-type human rhodopsin cDNA and 5 0 -UTR (collectively 1.8 kb) expressed from a CMV promoter. The design of the shRNA sequences was based on a combination of hand selection using variables recommended by OligoEngine (www.OligoEngine.com) and use of on-line software provided by Dharmacon, OligoEngine, Genscript and Invitrogen. The shRNA sequences target human rhodopsin codons 55-61, 73-79, 188-195 and the constructs are referred to as pSuperRhoi1/GFPQ, pSuperRhoi2/GFPQ and pSuperRhoi3/GFPQ, respectively ( Figure 2a ). The approximate region targeted by the shRNA associated with pSuperRhoi1/GFPQ (henceforth the shRNAs are referred to as Rhoi1, Rhoi2 and Rhoi3) was recommended by each of the four programs tested, whereas Rhoi2-and Rhoi3-targeted regions were recommended by three each out of four programs tested. Comparison of the shRNA sequences with available mammalian data (NCBI BLAST) revealed no complete homology with genes other than rhodopsin. We speculated that silencing of an ectopic transgene in a population of cells would be limited by the number of cells that expressed the transgene but were not concomitantly transfected with the shRNA construct. In order to identify and quantitate the cells that contained both the rhodopsin expression constructs and shRNA constructs from those that contained only one of these, we cloned a red fluorescent protein (RFP) expression cassette into the plasmid expressing rhodopsin (pCMVRhoRFP) and a GFP expression cassette into the shRNA expressing plasmid (pSuper/GFPQ) ( Figure 2a ). In this case, a GFP transgene (GFPQ, Qbiogene) was used that does not contain the target sequence complementary to the RNAi expressed by pSuperGFPi, allowing pSuperGFPi to be used as a nonspecific control within the same cell expressing GFPQ. Resistance to silencing of GFPQ by pSuperGFPi was confirmed experimentally (data not shown). The presence of the RFP transgene on the same plasmid that expresses rhodopsin allows for accurate normalization of transfection efficiency in our rhodopsin-silencing experiments. Similar to the experiments described above for silencing of GFP, 911 cells were cotransfected with either pCMVRhoRFP and one each of the shRNA constructs targeting rhodopsin. These transfections were performed For Western analysis, unboiled protein lysates were electrophoresed through a 12% Tris-glycine polyacrylamide gel and rhodopsin protein detected using the monoclonal antibody Rho1D4 and RFP was detected using DsRed monoclonal antibody purchased from Clontech. Northern blot was performed using an 1.8 kb XhoI/BamHI fragment of pCMVRho and a 0.7 kb BamHI/NotI fragment of pDsRed2-N1. Quantitation was performed using QuantityOne software (BioRad). pSuper/GFPQ was constructed by cloning a GFP expression cassette derived from pQBI25-fa1 (Qbiogene) into pSuper. pSuperRhoi1/GFPQ, pSuperRhoi2/GFPQ and pSuperRhoi3/GFPQ were constructed by annealing the oligonucleotide pairs RHOi1-F, RHOi1-R; RHOi2-F, RHOi2-R and RHOi3-F, RHOi3-R into pSuper/GFPQ. Oligonucleotide sequences were RHOi1-F (5 0 -GATCCCCCTTCCTCACGCTCTACGTCTTCAAGAGAGACGTAGAGCGTGAGG AAGTTTTTGGAAA-3 0 ) and RHOi1-R (5
0 ) and RHOi3-R (5 0 -AGCTTTTCCAAAAAAATCGACT ACTACACGCTCAATCTCTTGAATTGAGCGTGTAGTAGTCGATTGGG-3 0 ). pCMVRhoRFP contains the 1.8 kb human rhodopsin cDNA and 5 0 -UTR in pcDNA3.1(À) (Invitrogen) and an RFP expression cassette derived from pDsRed2-N1 (Clontech).
Rhodopsin silencing by RNAi SM Cashman et al silencing by the shRNA. Hence, under these experimental conditions, the theoretical maximum expected silencing of rhodopsin is estimated at 96.5%. Our experimental results indicate that Rhoi2, which targets codons 73-79, was able to silence rhodopsin by 94.3472.17% at the protein level when assessed by Western blot analysis (Figure 2c ). Silencing of rhodopsin by Rhoi1, which targets codons 55-61, was observed to be moderate and variable (34.8712.7%), and we found no silencing of rhodopsin by Rhoi3 (Figure 2c) . Silencing of rhodopsin in these experiments by Rhoi2 and Rhoi1 was examined further by Northern blot analysis, which indicated a silencing of rhodopsin mRNA of 63.070.4 and 21.875.54% by Rhoi2 and Rhoi1, respectively (Figure 2d) .
Given that the rhodopsin cDNA was expressed by the very potent CMV promoter (that shows robust expression of GFP in 911 cells), the level of silencing achieved is quite remarkable. This particular shRNA (Rhoi2) is also very promising, because to the best of our knowledge, no mutations in rhodopsin have so far been reported in the region targeted by this shRNA (www.retinainternational.com). Although Rhoi1 was less efficient than Rhoi2 in silencing rhodopsin, it has an advantage that it also targets murine rhodopsin by virtue of sequence homology in the target region between mouse and human rhodopsin. Thus, Rhoi1 may have utility in the study of rhodopsin expression and function in mice.
In order to examine whether Rhoi2 and Rhoi1 could also silence a mutant human rhodopsin mRNA, we mutagenized the human rhodopsin cDNA such that the codon for proline (CCC) at position 23 was converted to histidine (CAC) -pCMVRhoP23HRFP (Figure 3a) . The P23H mutation is the most commonly found mutation in autosomal dominant RP patients in the United States. In experiments similar to those described above, we observed silencing of P23H rhodopsin of 94.971.9% by Rhoi2. In addition, Rhoi1 silenced P23H rhodopsin by 58.073.5% despite its moderate silencing of wild-type rhodopsin (Figure 3b ). We attribute this observation to the potential differences in secondary and tertiary mRNA structures between normal and P23H rhodopsin mRNA, either due to a specific effect on structure of the Rhoi1 target region or a nonspecific effect of differences in stabilities of mutant and wild-type mRNAs. A reduced stability of the P23H rhodopsin protein has been observed previously, 11 and it is possible that this instability could amplify any degrading effects of Rhoi1. 0 ) for the first round of PCR, generating a 365 bp product using pCMVRho as template, which was followed by an asymmetric PCR for five cycles and completed with 25 PCR cycles containing primer RhoMR2 (5 0 -AAAAGACTCGTTGTTG ACCTCCG-3 0 ). The 888 bp mutagenized product was cloned into pCMVRho, replacing the wild-type rhodopsin sequence with P23H and verified by sequencing. An RFP cassette was added as described above for pCMVRhoRFP. pCMVRhoR2RFP was constructed in a manner similar to pCMVRhoP23H, except that primer Rhoi2MR (5 0 -GCCACGGCCAAATTCAATAAAATATAATTGAGAGGCGTGCGCAGCTTCTT-3 0 ) was used instead of P23HR.
Rhodopsin silencing by RNAi SM Cashman et al However, this would be inconsistent with our observation that P23H and normal rhodopsin protein are present at equal levels in transfected 911 cells (Figure 3d ). Rhoi1 may have unexpected uses in aiding to accelerate degradation of the naturally destabilized P23H rhodopsin without the need for trans complementation. This needs to be determined. Indeed, an 11-15% decrease in P23H rhodopsin expression is sufficient to provide some rescue of transgenic rats expressing P23H rhodopsin at 25% of the normal rhodopsin levels. 12 Since Rhoi2 and Rhoi1 are designed to target codons 73-79 and 55-61, respectively, their ability to silence mRNA with a mutation at codon 23 indicates that these shRNA molecules would function mutation independently, except of course where the mutation lies within the small region targeted by the shRNA. In such circumstances, combining two shRNA molecules (redundancy) in one construct may be a possible strategy to target mutations that lie within the target site of any one shRNA molecule. A condition that remains to be determined is whether some mutations in rhodopsin may alter the secondary or tertiary structure of the target mutant mRNA such as to mask the shRNA target site, potentially requiring alternative shRNAs for cleavage of those specific transcripts.
Given that we observed consistent silencing of mutant and wild-type rhodopsin with Rhoi2, we attempted to use the degeneracy of the genetic code to construct a rhodopsin transgene that would code for a normal rhodopsin protein via a cmRNA. The use of such a transgene would be to trans complement both mutant and normal rhodopsin mRNA that were silenced by the shRNA. Specifically, we altered 10 of the 21 nucleotides that encode aa 73-79 of human rhodopsin (pCMVRhoR2RFP) -that region targeted by Rhoi2 (Figure 3c) . As above, an RFP expression cassette was incorporated into this construct to allow for normalization of transfection efficiency. One concern with a cmRNA would be whether the cmRNA is translated as efficiently as the wild-type mRNA. Hence, we compared rhodopsin protein levels from pCMVRhoRFP, pCMVRhoP23HRFP and pCMVRhoR2RFP in transfected 911 cells. We found that there was no detectable difference in rhodopsin protein levels between these constructs (Figure 3d ). Indeed, given that rhodopsin is the most abundant protein in the rod photoreceptors, it is an important observation that the translation of the cmRNA is equivalent to that of normal rhodopsin mRNA, possibly indicative that the cmRNA may efficiently substitute the functions of wild-type rhodopsin mRNA. In order to examine whether the cmRNA was indeed resistant to Rhoi2, we cotransfected pCMVRhoR2RFP and pSuperRhoi2/GFPQ into 911 cells. As a control, we cotransfected pCMVRhoR2RFP with pSuperGFPi/GFPQ. We observed no difference in total rhodopsin protein levels between these two experiments, indicating that the novel rhodopsin cmRNA is indeed resistant to Rhoi2 (Figure 3e ). Apart from alteration of the target sequence for Rhoi2, a contributor to complete resistance might have been the reduced GC content from 43 to 10% in that region, thereby weakening the shRNA:cmRNA binding energy.
Having separately demonstrated that both normal and mutant human rhodopsin mRNA can be silenced by an shRNA, and that an shRNA-resistant rhodopsin transgene can be synthesized, we examined whether the system can work in concert, that is, can we simultaneously silence a mutant rhodopsin mRNA with an shRNA and in that same cell express a cmRNA that leads to expression of normal rhodopsin. The goal of this experiment was to obtain proof of principle to overcome the dynamics of the complex reaction rather than simulate autosomal dominant retinitis pigmentosa in vivo. Discrimination between normal rhodopsin and P23H rhodopsin protein is possible because of the consistently different migration patterns of these two proteins on a Tris-glycine gel (Figure 3f) . In our experiments, we consistently found a single rhodopsinpositive band for normal rhodopsin and three different species (oligomers) with the P23H rhodopsin that migrated differently from normal rhodopsin (Figure 3f,  lanes 3 and 4) . Similar oligomerization of mutant rhodopsin has been reported previously. 13 Cotransfection of pCMVRhoP23HRFP and pCMVRhoR2RFP with a nonspecific shRNA into 911 cells reconstitutes the four expected 'species' of rhodopsin ( Figure 3f, lane 1) . However, when the nonspecific shRNA is replaced by an shRNA targeting normal (and simultaneously P23H) rhodopsin in the cotransfection, the oligomers associated with P23H are no longer detectable by Western blot, while the band associated with normal (shRNA-resistant) rhodopsin remains unaffected (Figure 3f, lane 2) . Quantitation of the Western blot indicates silencing of P23H rhodopsin by 90.6475.19%. Owing to the unavailibility of appropriate antibodies against P23H rhodopsin, an experiment that more accurately simulates autosomal dominant retinitis pigmentosa in cell culture is technically challenging at this time.
Previous mRNA replacement strategies using ribozymes have focused on performing the reactions in a test tube, 5, 14, 15 where the reaction conditions can be finely controlled and do not represent the complexity of proteins present in the cell. Our coexpression experiments demonstrating that it is possible to specifically silence P23H rhodopsin mRNA in the presence of an shRNA-resistant rhodopsin mRNA in the context of a cell significantly advances these previous observations and is significant proof of principle that an approach involving RNAi may work in animal models and humans with retinal degeneration.
The next step in this study is to attempt knock down of human rhodopsin in transgenic animal models or RP. Several laboratories including our own are developing methods of safe, efficient and targeted gene transfer to the retina. Some of the potential problems that might be encountered in vivo include innate immune responses against RNAi, induction of interferon or off target silencing of multiple other genes. Despite these potential drawbacks, mutation-independent silencing of genes by RNAi holds great promise.
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